Stepping down inhaled corticosteroids in asthma: Randomised controlled trial

British Medical Journal

Volumn 326, Issue 7399, 2003, Pages 1115-1118

  Hawkins, Gillian ^a   McMahon, Alex D ^a   Twaddle, Sara ^b   Wood, Stuart F ^a   Ford, Ian ^a   Thomson, Neil C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b STOBHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE;

ADULT; ADVERSE DRUG REACTION; ARTICLE; ASTHMA; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM;

ADMINISTRATION, INHALATION; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; CHRONIC DISEASE; DOUBLE-BLIND METHOD; HEALTH STATUS; HUMANS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0037901033     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998;157(suppl):S1-S53.
2. British Guidelines on the Management of Asthma. Thorax 2003;58(suppl1):S1-S96.
3. Global Initiative for Asthma. Global strategy for asthma management and prevention. Bethesda (MD): NHLBI/WHO Workshop Report 1995. (Publication no 95-3659.)
4. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. Arch Intern Med 1999;159:941-55.
5. Haahtela T, Jarvinnen M. Kava T, Kiviranta K, Sirkka K, Lehtonen K, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994:331:700-5.
6. Leuppi J, Salome CM, Jenkins CR, Anderson SD, Xuan W, Marks GB, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001;163:406-12.
7. Wilding P, Clark M, Coon JT, Lewis S, Rushton L, Bennett J, et al. Effect of long term treatment with salmeterol on asthma control: a double blind randomised crossover study. BMJ 1997;314:1441-6.
8. Lemanske RF Jr, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, et al. Inhaled corticosteroid reduction and elimination in patients with persistant asthma receiving salmeterol: a randomised controlled trial. JAMA 2001;285:2594-603.
9. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-34.
10. Rimmington LD, Aronoffsky L, Mowatt A, Whaburton E, Ryland I, Pearson MG. Use of a simple patient focussed asthma morbidity score. Eur Respir J 1997;11:1289.
11. Dekker FW, Dieleman FE, Kaptein AA, Mulder JD. Compliance with pulmonary medication in general practice. Eur Respir J 1993;6:890.
12. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. Am Rev Respir Dis 1992;145:1321-7.
13. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
14. Wong CA, Walsh LJ, Smith CJP, Wisnieswski AF, Lewis SA, Hubbard R, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000;355:1399-403.
15. Gershman NH, Wong HH, Liu JT, Fahy JV. Low and high-dose fluticasone propionate in asthma: effects during and after treatment. Eur Respir J 2000;15:11-8.
16. Holt S. Suder A, Weatherall M, Cheng S, Shirtclifie P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001;323:253-6.
17. Bousquet J, Ben-Joseph R, Messonnier M, Alemao E, Gould AL. A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin. Ther 2002;24:1-20.
18. McMahon AD. Study control, violators, inclusion criteria and defining explanatory and pragmatic trials. Stat Med 2002;21:I365-76.
19. Roland M, Torgerson DJ. Understanding controlled trials: What are pragmatic trials? BMJ 1998;316:285.
20. Tattersfield AE, Harrison TW. Step 3 of the asthma guidelines. Thorax 1999;54:753-4.
21. Althuis MD, Sexton M, Prybylski D. Cigarette smoking and asthma symptom severity among adult asthmatics. J Asthma 1999:36:257-64.